Concord Biotech Share Price

Concord Biotech Share Price

NSE: CONCORDBIO
|
Pharmaceuticals
|
S Cap
₹ 1,452.80
-₹11.70 (-0.8%)
1D
Last updated 10 Sep, 2026, 15:50 IST

Concord Biotech Share Price Today

As of 11 Sep 2026, Concord Biotech share price is ₹1,452.80. The stock opened at ₹1,472.20, compared to its previous close of ₹1,464.50. During today's trading session, Concord Biotech share price moved in the range of ₹1,432.00 to ₹1,472.20, with an average price of ₹1,452.10 for the day. Looking at its last 52-week, the stock has touched a low of ₹987.00 and a high of ₹1,704.00. On the performance front, Concord Biotech share price has increased by 21.35% over the last six months and is down 13.02% on a year-on-year basis.

₹1,432.00
0.80% down today
₹1,472.20
1D LOW
1D HIGH

Concord Biotech Returns Calculator

Circuit
L
H
₹1,162.30
₹1,743.30
52-week
L
H
₹987.00
₹1,704.00

About Concord Biotech

Concord Biotech Share Price
ISIN
INE338H01029
Sector Market Cap
₹ 15,196.55 Cr

Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical ingredients (API), finished formulations, and contract development and manufacturing services. It manufactures API through fermentation and semi-synthetic processes and finished formulations. The Company’s offerings span both biopharmaceutical APIs and formulations across therapeutic areas like immunosuppressants, oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in antibacterial, antifungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, and Teicoplanin. Its API products under development include Daptomycin, Idarubicin, and Pirarubicin.

Concord Biotech Financial Highlights

  • Revenue: Concord Biotech reported revenue of ₹1,107.25 crore in FY26 vs ₹1,244.54 crore in FY25. It showed a decrease of 11.03% on a yearly basis.
  • Operating Profit: Concord Biotech reported an operating profit of ₹344.65 crore in FY26 vs ₹494.55 crore in FY25. It showed a decrease of 30.31% on a year-on-year basis.
  • Net Profit: Concord Biotech reported a net profit of ₹259.23 crore in FY26 vs ₹371.64 crore in FY25. It showed a decrease of 30.25% on a yearly basis.

Concord Biotech Quarterly Result Highlights

  • Concord Biotech reported revenue of ₹270.32 crore in Jun 2026, compared with ₹341.43 crore in Mar 2026, representing a decrease of 20.83% on a quarter-on-quarter (QoQ) basis.
  • Concord Biotech reported an operating profit of ₹78.34 crore in Jun 2026, compared with ₹114.08 crore in Mar 2026, representing a decrease of 31.33% on a quarter-on-quarter (QoQ) basis.
  • Concord Biotech reported a profit of ₹57.70 crore in Jun 2026, compared with ₹88.47 crore in Mar 2026, reflecting a decrease of 34.78% on a QoQ basis.
  • The earnings per share (EPS) of Concord Biotech stood at ₹24.78 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
44.08%
FII
7.52%
Other DII
4.96%
Retail and other
39.03%
Mutual funds
4.40%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20258.03%
Dec 20257.58%
Mar 20267.80%
Jun 20267.52%
Mkt Cap Cr
15,196.50
P/E
55.70
P/B
7.53
ROE
12.94%
D/E
0.00
ROCE
17.08%
Div. Yield
0.52%
EPS(TTM)
25.17
Turnover
0.50
EV/EBITDA
34.85
Net Margin
24.95%
Op. Margin
40.43%
ROA
12.21%
Quick Ratio
5.50
Curr. Ratio
7.45
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Concord Biotech outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Concord Biotech appears overvalued compared to its peers
Step 1 of 5
Earnings
Very Poor
Concord Biotech revenue, operating profits and net profits have been degrowing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,48,316.0036.915.3513.74%0.6117.33%93.240.86%0.4810.90
Divis Laboratories2,51,737.0085.3614.9015.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,87,460.0086.9522.2925.49%1.6913.85%222.760.69%0.4958.70
Zydus Lifesciences1,12,618.0024.284.1118.59%0.3117.35%237.300.09%0.3335.38
Cipla1,10,515.0033.223.2411.27%0.0014.95%423.360.95%0.4543.52
Laurus Labs1,04,456.0095.9419.7416.77%0.4016.14%97.200.10%0.6713.72
Aurobindo Pharma97,238.9025.882.539.25%0.1911.76%394.820.24%0.3841.58
Lupin95,660.0017.094.2323.76%0.0424.88%659.000.87%0.57129.18
Dr. Reddy's Laboratories95,420.6029.912.5011.07%0.1812.54%377.950.70%0.4138.68
Mankind Pharma93,596.0044.875.6911.74%0.3413.13%396.980.04%0.4449.37

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Concord Biotech Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,054.89₹1,200.09₹1,016.94₹853.17
Other Income₹52.36₹44.45₹33.78₹35.31
Total Revenue₹1,107.25₹1,244.53₹1,050.72₹888.48
Total Expenses₹762.23₹748.66₹641.53₹568.42
Profit Before Tax₹344.65₹494.55₹412.57₹322.01
Tax₹85.42₹122.91₹104.46₹81.93
Profit After Tax₹259.23₹371.64₹308.10₹240.09
EPS - Basic₹24.78₹35.52₹29.45₹22.95
EPS - Diluted₹24.78₹35.52₹29.45₹22.95

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹344.65₹494.55₹412.57₹322.01
Income before WC changes₹381.21₹524.69₹450.00₹368.56
Change in Assets-₹10.48-₹216.44-₹73.97-₹79.46
Change in Liabilities-₹3.44₹45.68-₹7.21₹27.17
Change in WC-₹13.92-₹170.76-₹81.18-₹52.29
Cash flow from Operations₹266.88₹244.52₹265.47₹246.00
Cash flow from Investing-₹142.72-₹159.99-₹154.61-₹157.95
Cash flow from Financing-₹112.88-₹98.77-₹99.21-₹85.22
Total Cash Flow₹11.28-₹14.24₹11.64₹2.83
Cash (Start of the year)₹0.90₹15.14₹3.50₹0.67
Cash (End of the year)₹12.19₹0.90₹15.14₹3.50

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹984.62₹899.01₹804.48₹786.28
Current Assets₹1,250.11₹1,135.24₹896.23₹727.70
Total Assets₹2,234.73₹2,034.25₹1,700.71₹1,513.98
Current Liabilities₹169.08₹184.06₹142.16₹191.84
Net Current Asset₹1,081.03₹951.18₹754.08₹535.86
Non-Current Liabilities₹50.51₹37.47₹31.91₹32.14
Equity Capital₹2,015.14₹1,812.72₹1,526.65₹1,290.00
Total Equity & Liabilities₹2,234.73₹2,034.25₹1,700.71₹1,513.98

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,055.07₹1,200.09₹1,016.94₹853.17
Other Income₹52.73₹44.45₹33.78₹35.31
Total Revenue₹1,107.80₹1,244.53₹1,050.72₹888.48
Total Expenses₹753.09₹748.66₹641.53₹568.42
Profit Before Tax₹351.43₹495.88₹409.19₹320.05
Tax₹88.17₹122.91₹104.46₹81.93
Profit After Tax₹263.27₹372.96₹304.73₹238.13
EPS - Basic₹25.17₹35.65₹29.13₹22.76
EPS - Diluted₹25.17₹35.65₹29.13₹22.76

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹351.43₹495.88₹409.19₹320.05
Income before WC changes₹390.37₹524.69₹450.00₹368.56
Change in Assets-₹24.61-₹216.44-₹73.97-₹79.46
Change in Liabilities-₹4.51₹45.68-₹7.21₹27.17
Change in WC-₹29.12-₹170.76-₹81.18-₹52.29
Cash flow from Operations₹263.78₹244.52₹265.47₹246.00
Cash flow from Investing-₹142.28-₹159.99-₹154.61-₹157.95
Cash flow from Financing-₹114.51-₹98.77-₹99.21-₹85.22
Total Cash Flow₹6.98-₹14.24₹11.64₹2.83
Cash (Start of the year)₹0.90₹15.14₹3.50₹0.67
Cash (End of the year)₹7.89₹0.90₹15.14₹3.50

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹991.32₹898.94₹803.08₹786.95
Current Assets₹1,245.22₹1,135.24₹896.23₹727.70
Total Assets₹2,236.54₹2,034.18₹1,699.32₹1,514.65
Current Liabilities₹167.24₹184.06₹142.16₹190.53
Net Current Asset₹1,077.97₹951.18₹754.08₹537.17
Non-Current Liabilities₹49.54₹37.47₹31.91₹32.14
Equity Capital₹2,019.75₹1,812.65₹1,525.25₹1,291.98
Total Equity & Liabilities₹2,236.54₹2,034.18₹1,699.32₹1,514.65
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1452.8
102
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 102
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
6
Bullish
0
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
49.92
Neutral
ATR (14)
46.53
Neutral
STOCH(9,6)
44.59
Neutral
STOCH RSI (14)
22.72
Neutral
ADX(9)
20.72
Bearish
UO(9)
40.31
Neutral
ROC(12)
-6.15
Bearish
WillR(14)
-74.91
Neutral
Period
Simple value
Exponential vaue
5D
1449.62
1456.29
10D
1455.21
1462.79
20D
1496.55
1462.78
50D
1402.08
1410.8
100D
1299.41
1343.63
Volume trend — traded volume by day
10 Sep1L
9 Sep1L
8 Sep2L
7 Sep0L
4 Sep0L
Average1L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Concord Biotech Share Price
Concord Biotech
Pharmaceuticals
Add Stock
Add Another

Concord Biotech Share Price FAQs

Concord Biotech share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837